Ed Arce
Stock Analyst at WestPark Capital
(4.27)
# 436
Out of 5,105 analysts
406
Total ratings
47.04%
Success rate
18.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.73 | +90.09% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $34.83 | -13.87% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $9.31 | +1,317.83% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.23 | +1,103.85% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.46 | +704.29% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.66 | +351.81% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.46 | +191.48% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $6.25 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.19 | +404.20% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $13.30 | +426.51% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $36.10 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.07 | +5,796.81% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.23 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.23 | +413.64% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $220.65 | -84.14% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $65.00 | +10.77% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $571.44 | -29.13% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.21 | -11.43% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $36.23 | +162.21% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.71 | +6.16% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $37.25 | +28.86% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $45.00 | -83.33% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.45 | +1,011.11% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.85 | -17.98% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.11 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $49.80 | -49.80% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $17.57 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $37.08 | -81.12% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $48.63 | -56.82% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.15 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.73
Upside: +90.09%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $34.83
Upside: -13.87%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $9.31
Upside: +1,317.83%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.23
Upside: +1,103.85%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.46
Upside: +704.29%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.66
Upside: +351.81%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.46
Upside: +191.48%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.25
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.19
Upside: +404.20%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $13.30
Upside: +426.51%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $36.10
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.07
Upside: +5,796.81%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.23
Upside: +413.64%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $220.65
Upside: -84.14%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $65.00
Upside: +10.77%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $571.44
Upside: -29.13%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.21
Upside: -11.43%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $36.23
Upside: +162.21%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.71
Upside: +6.16%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $37.25
Upside: +28.86%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $45.00
Upside: -83.33%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.45
Upside: +1,011.11%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.85
Upside: -17.98%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $49.80
Upside: -49.80%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $17.57
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $37.08
Upside: -81.12%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $48.63
Upside: -56.82%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.15
Upside: -